Unexpected Dimebon Trial result PDF Print E-mail
ON the 3rd March sponsors announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer’s disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.

"The results from the CONNECTION study are unexpected, and we are disappointed for the Alzheimer’s community," said Dr. David Hung, president and chief executive officer of Medivation. "We are working with our colleagues at Pfizer to better understand the CONNECTION data and we plan to present these data at an upcoming medical meeting."

This is not only disappointing but surprising, and one is left with the question:- which of the recent trials is the most representative of the potential of Dimebon?

In view of the continued uncertainty and the danger of unwittingly discarding a useful medication, other trials are continuing as planned for the immediqate future.

 

More detail is available on http://www.tradingmarkets.com/news/press-release/mdvn_pfe_pfizer-and-medivation-announce-results-from-two-phase-3-studies-in-dimebon-latrepirdine-alzheimer-818695.html